MYGN Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -20.18% compared to Myriad Genetics's net margin of 14.45%. Myriad Genetics's return on equity of -17.13% beat Boston Scientific's return on equity of 9.57%.

Myriad Genetics has a consensus price target of $10.03, signalling upside risk potential of 157.93%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.89%. Given that Myriad Genetics has higher upside potential than Boston Scientific, analysts believe Myriad Genetics is more attractive than Boston Scientific.

Myriad Genetics has a beta of 2.009, which suggesting that the stock is 100.879% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Myriad Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Myriad Genetics quarterly revenues are $210.6M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Myriad Genetics's net income of -$42.5M is lower than Boston Scientific's net income of $674M. Notably, Myriad Genetics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 75.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics is 0.42x versus 8.72x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of -20.18% compared to Myriad Genetics's net margin of -1.73%. Myriad Genetics's return on equity of -17.13% beat Hologic's return on equity of 11.45%.

Myriad Genetics has a consensus price target of $10.03, signalling upside risk potential of 157.93%. On the other hand Hologic has an analysts' consensus of $67.96 which suggests that it could grow by 19.75%. Given that Myriad Genetics has higher upside potential than Hologic, analysts believe Myriad Genetics is more attractive than Hologic.

Myriad Genetics has a beta of 2.009, which suggesting that the stock is 100.879% more volatile than S&P 500. In comparison Hologic has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.552%.

Myriad Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Myriad Genetics quarterly revenues are $210.6M, which are smaller than Hologic quarterly revenues of $1B. Myriad Genetics's net income of -$42.5M is lower than Hologic's net income of -$17.4M. Notably, Myriad Genetics's price-to-earnings ratio is -- while Hologic's PE ratio is 23.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics is 0.42x versus 3.28x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of -20.18% compared to Myriad Genetics's net margin of 3.45%. Myriad Genetics's return on equity of -17.13% beat Repligen's return on equity of -1.16%.

Myriad Genetics has a consensus price target of $10.03, signalling upside risk potential of 157.93%. On the other hand Repligen has an analysts' consensus of $183.13 which suggests that it could grow by 48.59%. Given that Myriad Genetics has higher upside potential than Repligen, analysts believe Myriad Genetics is more attractive than Repligen.

Myriad Genetics has a beta of 2.009, which suggesting that the stock is 100.879% more volatile than S&P 500. In comparison Repligen has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.699%.

Myriad Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Myriad Genetics quarterly revenues are $210.6M, which are larger than Repligen quarterly revenues of $169.2M. Myriad Genetics's net income of -$42.5M is lower than Repligen's net income of $5.8M. Notably, Myriad Genetics's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics is 0.42x versus 10.66x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -20.18% compared to Myriad Genetics's net margin of 28.26%. Myriad Genetics's return on equity of -17.13% beat ResMed's return on equity of 25.76%.

Myriad Genetics has a consensus price target of $10.03, signalling upside risk potential of 157.93%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 7.94%. Given that Myriad Genetics has higher upside potential than ResMed, analysts believe Myriad Genetics is more attractive than ResMed.

Myriad Genetics has a beta of 2.009, which suggesting that the stock is 100.879% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Myriad Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Myriad Genetics pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Myriad Genetics quarterly revenues are $210.6M, which are smaller than ResMed quarterly revenues of $1.3B. Myriad Genetics's net income of -$42.5M is lower than ResMed's net income of $365M. Notably, Myriad Genetics's price-to-earnings ratio is -- while ResMed's PE ratio is 27.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics is 0.42x versus 7.20x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.